$4.46
6.69% yesterday
Nasdaq, Apr 03, 10:12 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Target price 2025 - Analyst rating & recommendation

Altimmune, Inc. Classifications & Recommendation:

Buy
90%
Hold
10%

Altimmune, Inc. Price Target

Target Price $22.38
Price $4.46
Potential
Number of Estimates 8
8 Analysts have issued a price target Altimmune, Inc. 2026 . The average Altimmune, Inc. target price is $22.38. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend Altimmune, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Altimmune, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Altimmune, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 0.02 0.00
95.35% 85.50%
EBITDA Margin -514,650.00% -4,122,978.05%
2,565.30% 701.12%
Net Margin -484,745.00% -3,407,069.63%
1,635.54% 602.86%

7 Analysts have issued a sales forecast Altimmune, Inc. 2025 . The average Altimmune, Inc. sales estimate is

$2.9k
Unlock
. This is
85.50% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$20.0k 0.00%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $20.0k 95.35%
2025
$2.9k 85.50%
Unlock
2026
$3.4k 17.24%
Unlock
2027
$48.9m 1,438,532.35%
Unlock
2028
$451m 821.52%
Unlock
2029
$635m 40.96%
Unlock

3 Analysts have issued an Altimmune, Inc. EBITDA forecast 2025. The average Altimmune, Inc. EBITDA estimate is

$-118m
Unlock
. This is
14.44% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-103m 0.42%
Unlock
, the lowest is
$-136m 31.66%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-103m 23.97%
2025
$-118m 14.44%
Unlock
2026
$-155m 31.40%
Unlock
2027
$-162m 4.66%
Unlock
2028
$-124m 23.70%
Unlock
2029
$-27.9m 77.45%
Unlock

EBITDA Margin

2024 -514,650.00% 2,565.30%
2025
-4,122,978.05% 701.12%
Unlock
2026
-4,508,628.40% 9.35%
Unlock
2027
-331.19% 99.99%
Unlock
2028
-27.42% 91.72%
Unlock
2029
-4.39% 83.99%
Unlock

4 Altimmune, Inc. Analysts have issued a net profit forecast 2025. The average Altimmune, Inc. net profit estimate is

$-97.3m
Unlock
. This is
0.40% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-89.1m 8.09%
Unlock
, the lowest is
$-114m 17.16%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-96.9m 19.28%
2025
$-97.3m 0.40%
Unlock
2026
$-102m 4.74%
Unlock
2027
$-106m 4.32%
Unlock
2028
$-43.4m 59.18%
Unlock
2029
$16.6m 138.33%
Unlock

Net Margin

2024 -484,745.00% 1,635.54%
2025
-3,407,069.63% 602.86%
Unlock
2026
-2,969,644.00% 12.84%
Unlock
2027
-217.43% 99.99%
Unlock
2028
-9.63% 95.57%
Unlock
2029
2.62% 127.21%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.34 -1.35
19.28% 0.75%
P/E negative
EV/Sales 74,634.23

4 Analysts have issued a Altimmune, Inc. forecast for earnings per share. The average Altimmune, Inc. EPS is

$-1.35
Unlock
. This is
0.75% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.23 8.21%
Unlock
, the lowest is
$-1.57 17.16%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.34 19.28%
2025
$-1.35 0.75%
Unlock
2026
$-1.41 4.44%
Unlock
2027
$-1.47 4.26%
Unlock
2028
$-0.60 59.18%
Unlock
2029
$0.23 138.33%
Unlock

P/E ratio

Current -3.33 46.20%
2025
-3.31 0.60%
Unlock
2026
-3.17 4.23%
Unlock
2027
-3.03 4.42%
Unlock
2028
-7.43 145.21%
Unlock
2029
19.39 360.97%
Unlock

Based on analysts' sales estimates for 2025, the Altimmune, Inc. stock is valued at an EV/Sales of

74,634.23
Unlock
and an P/S ratio of
120,224.01
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 10,661.50 1,210.70%
2025
74,634.23 600.04%
Unlock
2026
62,111.86 16.78%
Unlock
2027
4.36 99.99%
Unlock
2028
0.47 89.15%
Unlock
2029
0.34 29.06%
Unlock

P/S ratio

Current 17,174.00 1,250.16%
2025
120,224.01 600.04%
Unlock
2026
100,052.43 16.78%
Unlock
2027
7.02 99.99%
Unlock
2028
0.76 89.15%
Unlock
2029
0.54 29.06%
Unlock

Current Altimmune, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Apr 03 2025
Citizens Capital Markets
Locked
Locked
Locked Apr 02 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 18 2025
Citizens Capital Markets
Locked
Locked
Locked Mar 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 03 2025
William Blair
Locked
Locked
Locked Feb 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 05 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 03 2025
Locked
Citizens Capital Markets:
Locked
Locked
Apr 02 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 18 2025
Locked
Citizens Capital Markets:
Locked
Locked
Mar 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 03 2025
Locked
William Blair:
Locked
Locked
Feb 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 05 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today